Joaquin -Luben
VP, Head Clinical Development & Medical Affairs EMEA at Stemline Therapeutics Inc - New York, NY, US
Joaquin -Luben's Colleagues at Stemline Therapeutics Inc
Karen Driggs
Territory Sales Manager Hematology/Oncology, Ultra Orphan Drug, Rare Disease
Joaquin -Luben's Contact Details
646-502-2310
Spain
Stemline Therapeutics Inc
Joaquin -Luben's Company Details
Stemline is a commercial-stage biopharmaceutical company committed to applying our scientific leadership and commercial expertise to transform the lives of patients with cancer.ELZONRIS a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN. In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA).Inspired by the goal to improve outcomes for patients with unmet medical needs, Stemline is driven to discover and develop innovative therapeutics for the treatment of cancer. Currently our clinical-stage product candidates in include ELZONRIS, SL-701 and SL801.